Published guidance, NICE advice and quality standards | Guidance

Showing 171 to 180 of 334

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	TA638	1 July 2020	1 July 2020
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	TA639	1 July 2020	1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)	TA635	30 June 2020	30 June 2020
Archimedes for biopsy of suspected lung cancer	MIB211	11 June 2020	11 June 2020
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer	TA632	10 June 2020	10 June 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer	TA628	13 May 2020	13 May 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)	TA618	15 January 2020	15 January 2020
Lung cancer in adults	QS17	26 March 2012	13 December 2019
Irreversible electroporation for primary liver cancer	HTG532	27 November 2019	27 November 2019
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	TA612	20 November 2019	20 November 2019